FDA updates generic peptide drug guidance

FDA published 17 revised draft product‑specific guidances for generic peptide drugs, but none include sex‑disaggregated or reproductive‑stage evidence.

On July 28, 2026, FDA issued 17 revised draft product‑specific guidances for drugs including semaglutide, liraglutide, glucagon, teriparatide, calcitonin salmon, pegcetacoplan, tirzepatide and vosoritide ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/42278c2?reqfrom=share&utm_source=openai)). These guidances define how developers should demonstrate equivalence when seeking FDA approval for generic peptide drugs. The drafts outline expectations on impurity thresholds, higher‑order structure, innate immune response testing and biological activity assessment ([content.govdelivery.com](https://content.govdelivery.com/accounts/USFDA/bulletins/42278c2?reqfrom=share&utm_source=openai)).

Key takeaways

FDA released revised draft guidance for generic peptide products covering 17 specific peptides.
The guidances set expectations for ANDA submissions on impurities, structure, immune response, and biological activity.
The updates omit sex‑disaggregated evidence and any labeling relevant to reproductive stages.

What does the generic peptide guidance cover?

On July 28, 2026, FDA issued 17 revised draft product‑specific guidances for drugs including semaglutide, liraglutide, glucagon, teriparatide, calcitonin salmon, pegcetacoplan, tirzepatide and vosoritide (content.govdelivery.com). These guidances define how developers should demonstrate equivalence when seeking FDA approval for generic peptide drugs. The drafts outline expectations on impurity thresholds, higher‑order structure, innate immune response testing and biological activity assessment (content.govdelivery.com).

Do these guidances mention sex‑disaggregated or reproductive‑stage data?

The updated draft guidances make no reference to sex‑disaggregated data or reproductive‑stage labeling. They focus strictly on analytical and biophysical comparability—not on how outcomes may differ by sex or life stage. Clinicians and patients will find no explicit guidance on sex‑specific or reproductive‑related considerations for these generic peptides.

What does the FDA say about next steps?

FDA invites public comment on these draft guidances. The agency will consider feedback before issuing final versions (teleranked.com). Applicants developing other generic peptide products may request meetings through the Office of Generic Drugs (content.govdelivery.com).

Frequently asked questions

What is the generic peptide guidance?

The generic peptide guidance refers to 17 revised draft product‑specific guidances issued by FDA for generic versions of certain peptide drugs such as semaglutide, glucagon, liraglutide and teriparatide.

When did FDA publish the generic peptide guidance?

FDA published the 17 revised draft product‑specific guidances on July 28, 2026.

Does the guidance include sex‑disaggregated evidence?

No. The draft guidances do not include sex‑disaggregated evidence or analyses.

Are there recommendations for reproductive‑stage labeling in the guidance?

No. None of the revised draft product‑specific guidances address reproductive‑stage considerations or labeling.

What areas do the guidances address?

They address ANDA submission parameters including impurity thresholds, higher‑order structure, innate immune response testing, and biological activity assessment.

Are these guidances final?

No. These are draft guidances open for public comment. FDA will consider feedback before finalizing them. This article is for general information and is not medical advice. Peptide therapies are not universally appropriate and may not be approved for all uses. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment, especially if you are pregnant, planning pregnancy, or breastfeeding.

Published 2026-09-15

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.

Join the conversation

Comments are moderated. Please keep discussion focused on the evidence and avoid sharing personal health information.

Loading comments...